<DOC>
	<DOCNO>NCT02889523</DOCNO>
	<brief_summary>Phase I study design determine recommend phase II dose ( RP2D ) tazemetostat patient treat R-CHOP 21 . Phase II study design determine safety tazemetostat patient treat 8 cycle R-CHOP 21 determine complete response rate accord Cheson International Working Group ( IWG ) 2014 : Lugano Classification ( i.e . Deauville scale 1-3 ) 8 cycle Epi-RCHOP 21 .</brief_summary>
	<brief_title>Study Tazemetostat Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated Chemiotherapy</brief_title>
	<detailed_description>Phase I : Up 18 patient recruit , use conventional dose-escalation algorithm ( 3+3 patient per dose level ) identify maximum tolerate dose ( MTD ) deem RP2D . Patients receive 8 cycle RCHOP every 21 day tazemetostat every day , start day 2 cycle 1 . 4 cohort define , accord dose level tazemetostat : 400mg Twice day ( BID ) ( cohort 1 , start level ) , 600mg BID ( cohort 2 ) , 800mg BID ( cohort 3 ) , 200mg BID ( cohort -1 ) , depend observed toxicity . Phase II : Up 115 patient recruit treated tazemetostat MTD RCHOP . Patients receive 8 cycle RCHOP every 21 day tazemetostat MTD every day , start day 2 cyle 1 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients untreated DLBCL de novo transform indolent lymphoma ( CD 20 positive ) Ageadjusted International Prognostic Index ( aaIPI ) ≥ 2 Age 60 80 year include Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 ( 0 1 phase Ib ) Sied inform consent Life expectancy ≥ 90 day ( 3 month ) start tazemetostat Adequate renal function calculate creatinine clearance &gt; 40 mL/min local institutional formula Adequate bone marrow function define : absolute neutrophil count ( ANC ) ≥ 1500/mm3 ( ≥ 1.5 X 10 G/L ) Platelets ≥ 75,000/mm3 ( ≥ 75 X 10 G/L ) without platelet transfusion dependency last 7 day Hemoglobin ≥ 9 g/dL ( may receive transfusion ) Adequate liver function define : Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome Alkaline phosphatase ( absence bone disease ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 X ULN ( ≤ 5 X ULN lymphoma involvement liver ) Patients prior Hepatitis B virus ( HBV ) Hepatitis C virus ( HCV ) infection eligible Hepatitis B detection , surface antigen negative and/or HBV DNA undetectable , Hepatitis C detection , HCV RNA undetectable . Left ventricular ejection fraction ( LVEF ) &gt; 50 % echocardiography multiple gated acquisition ( MUGA ) scan Adequate tissue central retrospective test EZH2 mutation status cell origin ( 15 slide tumor biopsy must available screening ) Males partner childbearing potential must agree use reliable form contraception Symptomatic central nervous system meningeal involvement Contraindication drug contain chemotherapy regimen Prior treatment tazemetostat inhibitor EZH2 Patients undergo active treatment another malignancy ( exception include : A patient diseasefree 2 year , patient history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible ) Patients take medication know potent CYP3A4 inducers/inhibitors ( include St. John 's wort ) know substrate CYP2C9 Patients unwilling exclude Seville orange , grapefruit juice grapefruit diet Major surgery within 4 week first dose study drug ( minor procedure transcutaneous biopsy , central line placement permit within 2 week enrollment ) Inability take oral medication malabsorption syndrome uncontrolled gastrointestinal condition would harm ability take tazemetostat Significant cardiovascular impairment : congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable angina , myocardial infarction stroke within 6 month first dose tazemetostat ventricular arrhythmia Prolonged Fridericia 's Corrected QT Interval ( QTcF ) &gt; 480 msec Active uncontrolled infection require systemic therapy Congenital immunodeficiency know HIV ( human immunodeficiency virus infection ) Any major illness investigator 's judgement , substantially increase risk associate patient 's participation study Patients undergone solid organ transplant Previous treatment B cell lymphoma , except low dose radiotherapy follicular lymphoma glucocorticoid ( 14 day inclusion , 1 mg/kg/day maximum dose )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Front line therapy</keyword>
	<keyword>Age-adjusted International Prognostic Index ( aa-IPI ) &gt; 1</keyword>
	<keyword>60 80 year</keyword>
</DOC>